top of page

BlossomHill Therapeutics raises a $100M series B to work on precision medicine small molecules

Scientific founder, president & CEO J. Jean Cui describes her scientific approach of working to solve resistance mutations, and she previews three of BlossomHill's programs.



Comments


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page